Cardiol Therapeutics Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	-	-	-	0.08
Revenue Growth	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	0.08
Selling, General & Admin	20.18	20.3	26.26	15.56	22.37	27.87
Research & Development	15.67	14.02	14.01	14.22	18.96	10.87
Operating Expenses	35.86	34.32	40.28	29.79	41.34	38.74
Operating Income	-35.86	-34.32	-40.28	-29.79	-41.34	-38.66
Interest & Investment Income	0.7	0.73	1.19	2.04	1.24	0.11
Currency Exchange Gain (Loss)	0.3	-1.18	2.14	-0.71	2.76	1.89
Other Non Operating Income (Expenses)	0.78	0.95	0.27	0.33	6.41	5.03
Pretax Income	-34.08	-33.82	-36.68	-28.13	-30.93	-31.64
Net Income	-34.08	-33.82	-36.68	-28.13	-30.93	-31.64
Net Income to Common	-34.08	-33.82	-36.68	-28.13	-30.93	-31.64
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	102	87	72	64	63	43
Shares Outstanding (Diluted)	102	87	72	64	63	43
Shares Change	28.88%	21.55%	11.02%	3.13%	44.61%	44.77%
EPS (Basic)	-0.34	-0.39	-0.51	-0.44	-0.49	-0.73
EPS (Diluted)	-0.34	-0.39	-0.51	-0.44	-0.49	-0.73
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-24.1	-23.88	-25.08	-25.24	-27.3	-23.55
Free Cash Flow Per Share	-0.24	-0.28	-0.35	-0.39	-0.44	-0.55
Gross Margin	-	-	-	-	-	100.00%
Operating Margin	-	-	-	-	-	-49091.93%
Profit Margin	-	-	-	-	-	-40170.45%
Free Cash Flow Margin	-	-	-	-	-	-29904.22%
EBITDA	-35.85	-34.28	-39.97	-29.59	-41.16	-38.44
D&A For EBITDA	0.01	0.04	0.31	0.2	0.18	0.22
EBIT	-35.86	-34.32	-40.28	-29.79	-41.34	-38.66

SEC Filings: 10-K · 10-Q